Manulife (Manufacturers Life Insurance)
OBIO icon

Manulife (Manufacturers Life Insurance)’s Orchestra BioMed OBIO Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-32,518
Closed -$135K – 2885
2025
Q4 		$135K Hold
32,518
– – ﹤0.01% 2647
2025
Q3 		$80.6K Hold
32,518
– – ﹤0.01% 2815
2025
Q2 		$87.1K Sell
32,518
-9,466
-23% -$27.6K ﹤0.01% 2790
2025
Q1 		$180K Buy
41,984
+4,975
+13% +$24.7K ﹤0.01% 2527
2024
Q4 		$148K Buy
37,009
+3,704
+11% +$19.9K ﹤0.01% 2722
2024
Q3 		$171K Sell
33,305
-8,777
-21% -$57.3K ﹤0.01% 2720
2024
Q2 		$343K Buy
42,082
+3,245
+8% +$18.8K ﹤0.01% 2357
2024
Q1 		$205K Sell
38,837
-1,105
-3% -$7.49K ﹤0.01% 2590
2023
Q4 		$365K Buy
39,942
+1,588
+4% +$10.8K ﹤0.01% 2311
2023
Q3 		$334K Buy
38,354
+5,571
+17% +$37.5K ﹤0.01% 2317
2023
Q2 		$229K Buy
32,783
+265
+0.8% +$4.02K ﹤0.01% 2532
2023
Q1 		$636K Buy
+32,518
New +$377K ﹤0.01% 1858

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s OBIO Position: Q1 2026 in Review

Manulife (Manufacturers Life Insurance) sold out of Orchestra BioMed (OBIO) in Q1 2026, closing a stake of 32,518 shares — an estimated $135K sold.

Manulife (Manufacturers Life Insurance) first reported a position in OBIO in Q1 2023 and held it in 12 quarters. The position peaked at $636K in Q1 2023. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • Manulife (Manufacturers Life Insurance) reported no remaining Orchestra BioMed position as of Q1 2026 after selling out during the quarter.
  • Manulife (Manufacturers Life Insurance) sold 32,518 Orchestra BioMed shares in Q1 2026, an estimated $135K.
  • Manulife (Manufacturers Life Insurance) first reported a position in Orchestra BioMed in Q1 2023 and held it in 12 quarters.
  • Manulife (Manufacturers Life Insurance)'s Orchestra BioMed position peaked at $636K in Q1 2023.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.